The Eph receptor tyrosine kinases are overexpressed in many pathologic tissues and have therefore emerged as promising drug target candidates. However, there are few molecules available that can selectively bind to a single Eph receptor and not other members of this large receptor family. Here we report the identification by phage display of peptides that bind selectively to different receptors of the EphB class, including EphB1, EphB2, and EphB4. Peptides with the same EphB receptor specificity compete with each other for binding, suggesting that they have partially overlapping binding sites. In addition, several of the peptides contain amino acid motifs found in the G-H loop of the ephrin-B ligands, which is the region that mediates high-affinity interaction with the EphB receptors. Consistent with targeting the ephrin-binding site, the higheraffinity peptides antagonize ephrin binding to the EphB receptors. We also designed an optimized EphB4-binding peptide with affinity comparable to that of the natural ligand, ephrin-B2. These peptides should be useful as selective inhibitors of the pathological activities of EphB receptors and as targeting agents for imaging probes and therapeutic drugs.
The Eph receptors are a large family of receptor tyrosine kinases that regulate a multitude of biological processes in developing as well as adult tissues by binding a family of ligands called ephrins (1, 2) . The Eph receptors have been implicated in a variety of pathological processes, including tumor progression (3) (4) (5) , pathological forms of angiogenesis (6) (7) (8) , chronic pain following tissue damage (9) , inhibition of nerve regeneration after spinal cord injury (10) , and human congenital malformations (11, 12) . Furthermore, these receptors have been reported to play a role in the balance of stem cell self-renewal versus cell-fate determination and differentiation (13) (14) (15) . Clearly, the ability to perturb Eph receptor-ephrin interactions could have a number of important medical applications-in addition to allowing a better understanding of the biological activities of these proteins. Therefore, it would be desirable to inhibit the pathological function of an Eph receptor without affecting other related Eph receptors required for normal physiological processes.
The ephrin ligands can discriminate between the EphA and EphB classes of receptors. Ephrin-A ligands bind to EphA receptors, with the exception of ephrin-A5 which at high concentrations can bind to EphB2 (16) . Ephrin-B ligands bind to EphB receptors as well as EphA4 (17, 18) . However, interactions between Eph receptors and ephrins belonging to the same class are highly promiscuous (1, 18, 19) . Nevertheless, several 12 amino acid-long peptides identified by phage display bind selectively to one or few Eph receptors of the A class (20, 21) . These peptides have some sequence similarity with the 15 amino acid-long G-H loop of the ephrins, which is the main region mediating high affinity binding of the ephrins to the Eph receptors (22) . In particular, several of the EphA receptor-binding peptides contain the motif W xxW (where "x" is a nonconserved amino acid and W is an aromatic amino acid (23) ), which is also found in the G-H loop of A-class ephrins. These peptides have additional distinctive sequence features that presumably confer their binding selectivity for specific EphA receptors. Importantly, micromolar concentrations of peptides that bind to EphA2 and EphA4 inhibit ephrin binding to these receptors (20, 21) . Interestingly, the EphA4-binding peptides are antagonists that inhibit receptor activation by ephrins (21) , whereas the EphA2-binding peptides behave as ephrin mimics and promote EphA2 activation and downstream signaling (20) (Koolpe and Pasquale, unpublished data) . The antagonistic peptides likely function by preventing ephrindependent Eph receptor clustering and transphosphorylation, which are necessary steps to activate downstream signaling pathways (1, 2) . In fact, the cell surface-anchored ephrins promote the formation of Eph receptor dimers as well as larger clusters in which the receptors become activated (22) , but soluble monomeric forms of the ephrins act as antagonists (24) . In contrast, it is currently unclear how the EphA2-binding peptides can activate EphA2.
Here we report the identification of antagonistic peptides that selectively bind to Eph receptors of the B class, including EphB1, EphB2, and EphB4. Furthermore, sequence optimization of one of the EphB4-binding peptides yielded a remarkably potent antagonist with affinity comparable to that of an ephrin ligand.
MATERIALS AND METHODS
Phage Display-An M13 phage library (New England Biolabs, Beverly, MA) displaying random 12-mer peptides was used for panning with EphB receptors. Histidine-tagged EphB ectodomain Fc fusion proteins (R&D Systems, Minneapolis, MN) were incubated overnight at 4ºC in nickel-nitrilotriacetic acid (Ni-NTA)-coated ELISA wells at concentrations of 10 mg/ml in Tris-buffered saline (TBS) (150 mM NaCl, 50 mM Tris-HCl, pH 7.5), except for EphB2 and EphB4 rounds 3.2 and 4, which were with 1mg/ml. Wells were blocked for 1 hour with 0.5% bovine serum albumin (BSA) in TBS, and rinsed with binding buffer (TBS, 1 mM CaCl 2 , 0.1% Tween-20 or 0.5% Tween-20 for EphB2 and EphB4 rounds 3.2 and 4). In round 1 of panning, 2x10 11 plaque forming units (PFUs) of the phage library in 100 ml binding buffer were incubated for 1 hour at room temperature in the EphB receptor-coated wells. After washing, remaining bound phage were eluted for 10 min with 100 ml of 0.2 M glycineHCl, pH 2.2, and neutralized with 15 ml of 1 M Tris-HCl, pH 9. The entire eluate was used to infect early-log phase ER2738 host bacteria and amplified for 4.5 hours at 37ºC. The phage were concentrated and stored according to the manufacturer's recommendations. In following rounds 2x10 11 PFUs of the amplified phage pool from the previous round were added to an EphB Fc-coated well and a BSA coated well. The phage were panned as described for round 1, except eluted phage were titered prior to amplification to assess enrichment.
Synthetic Peptid e s -Peptides were s y n t h e s i z e d u s i n g F m o c ( N -( 9 -fluorenly)methoxycarbonyl) chemistry and purified by high pressure liquid chromatography. Biotinylated peptides were synthesized with a carboxy-terminal GSGSK linker with biotin attached to the lysine side chain or with a carboxyterminal GSGS sequence linked to a carboxyterminal N-biotinyl-N'-Fmoc-ethylenediamine (Novabiochem). Matrix-assisted laser desorption ionization-time of flight mass spectrometry was used to verify proper peptide synthesis, and purity. Stock solutions of the peptides were dissolved in phosphate buffered saline (PBS, Irvine Scientific) and the pH was verified to be ~6.5. The WHWT peptide had low solubility in aqueous buffers and was therefore solubilized in 15% DMSO in PBS. Peptide concentrations were calculated based on OD 280 .
ELISA Assays-Phage binding to Ni-NTA wells coated with 1 mg/ml Eph receptor Fc fusion proteins was quantified using an anti-phage antibody conjugated to horseradish peroxidase (M13 phage detection kit, Amersham Biosciences) w i t h 2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) as a substrate. The background that was subtracted from the measurements was determined without EphB4 Fc.
To measure peptide competition of phage binding to EphB receptors, Ni-NTA wells coated with Eph ectodomain Fc were incubated for 30 min at room temperature with various peptide concentrations in binding buffer (100 ml/well). Concentrated stocks of phage clones diluted between 1:500 and 1:10,000 in binding buffer were then added to the wells for an 1 hr at room temperature. Wells were washed and bound phage were detected using the anti-M13 antibody. A biotinylated control peptide with sequence unrelated to the sequences of the Eph-binding peptides (RTVAHHGGLYHTNAEVK) was used as a negative control in some of the experiments, as indicated in the figure legends.
To measure the specificity of peptide binding ). Ephrin-B2 AP was co-incubated for 1 hr with different peptide concentrations in Ni-NTA wells coated with 1 mg/ml Eph receptor Fc. After several washes, the amount of ephrin-B2-AP b o u n d w a s q u a n t i f i e d u s i n g pnitrophenylphosphate as a substrate. Alkaline phosphatase activity from wells without EphB Fc was subtracted as background.
Immunoprecipitation, Peptide Pull-Down, and Immunoblotting-MCF-7 human breast cancer cells, which endogenously express EphB4, were grown in Minimum Essential medium Eagle (MEM) (ATCC) with 10% fetal bovine serum, 0.01 mg/ml bovine insulin, and Pen/Strep. COS cells, which endogenously express EphB2, and 293 human embryonal kidney (HEK) cells were grown in Dulbecco's Modified Eagles medium (DME) with high glucose (Irvine Scientific) with 10% fetal calf serum, sodium pyruvate, and Pen/Strep. Ten cm plates of 293 HEK cells were transfected with 9 mg EphB4 cDNA in pcDNA3, and 1 mg of an enhanced green fluorescent protein plasmid (BD Biosciences Clontech) to verify transfection efficiency, using SuperFect transfection reagent (Qiagen). The cells were passaged 1 day after transfection and used for pulldown experiments 2 days after transfection.
For peptide pull-down experiments, cells in 60 cm plates at 70% confluency or adult mouse brain tissue were solubilized in pull-down buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton-X100, 5 mM KCl and 1 mM EDTA). Three m g biotinylated peptide were incubated for 45-90 min with 5 ml streptavidin agarose beads (Sigma), unbound peptide was washed away, and the beads were incubated with the cell lysates for 45-90 min. Proteins bound to the beads were separated by SDS-polyacrylamide gel electrophoresis and probed by immunoblotting with EphB1, EphB2, or EphB4 antibodies. The EphB1 antibody (Santa Cruz) was detected with a secondary anti-goat IgG peroxidase-conjugated antibody (BioRad Laboratories). The EphB2 and EphB4 antibodies were affinity-purified polyclonal antibodies to GST fusion proteins containing approximately 100 amino acids from the the carboxy-terminal tails of the EphB2 or EphB4 receptors (8, 25) and were detected with a secondary anti-rabbit IgG peroxidase-conjugated antibody (Amersham Biosciences).
For EphB2 immunoprecipitations, COS cells were serum-starved in DME high glucose for 3 hrs prior to stimulation with 1 mg/ml ephrin-B1 Fc or Fc protein in the presence or absence of EphB2-binding peptides or a control peptide. For EphB4 immunoprecipitations, MCF-7 cells were stimulated with 0.5 mg/ml ephrin-B2 Fc or Fc protein in the presence or absence of the TNYL-RAW peptide. After ephrin stimulation, the cells were lysed in modified RIPA buffer (150 mM NaCl, 1 mM EDTA, 1% TritonX-100, 1% Na deoxycholate, 0.1 % SDS, 20 mM Tris pH 8.0) with protease inhibitors and 1 mM sodium orthovanadate. Cell lysates were used for immunoprecipitation with either 5 mg EphB2 antibodies or 10 m g EphB4 antibodies. The immunoprecipitates were eluted by boiling in 2X SDS sample buffer, separated by SDSpolyacrylamide gel electrophoresis and probed by immunoblotting with peroxidase-conjugated antiphosphotyrosine antibody (Transduction Laboratories, San Diego, CA). The immunoblots were then stripped and reprobed with either EphB2 antibody or a monoclonal EphB4 antibody (Zymed) followed by a secondary anti-rabbit IgG or anti-mouse peroxidase-conjugated antibody.
Cell Morphology-COS cells were plated onto glass coverslips and sixteen hours later were starved for three hours in DME with 0.5% fetal calf serum. The cells were then incubated for 20 min with 400 mM SNEW or control peptide in PBS, or an equal volume of PBS as a control, and then either left untreated or stimulated for 10 min with 1.5 mg/ml ephrinB1-Fc (R&D Systems, Inc.). The cells were then fixed in 4% formaldehyde, permeabilized in 0.1% TritonX-100 in PBS, stained with Alexa 594-labeled phalloidin (Molecular Probes), and mounted on glass slides. o C. After labeling, the cells were fixed in 4% formaldehyde/4% sucrose for 10 min and permeablized for 5 min with 0.05% Triton-X100 in PBS. The nuclei were counterstained with DAPI and the coverslips were mounted with ProLong Gold mounting media (Molecular Probes) onto glass slides and imaged under a fluorescence microscope.
RESULTS

Identification of Peptides that Bind to
Different EphB Receptors-To identify EphB receptor-binding peptides, an M13 phage library displaying random 12 amino acid-long peptides was panned on the ectodomains of EphB1, EphB2, or EphB4 fused to human Fc and immobilized on nickel-coated wells through a carboxy-terminal hexahistidine tag (Fig. 1) . Two panning experiments were performed with EphB4 because the first panning ( Fig. 1 , bottom left) yielded receptor-binding phage clones displaying only three different sequences (Table 1 ). In some rounds of panning, we used less receptor for coating the wells in the attempt to isolate phage clones with higher binding affinity ( Fig. 1 legend) .
Individual phage clones from different rounds of panning were confirmed to bind to the EphB receptor used for their isolation, sequenced to identify the displayed peptides, and named based on the initial 4 or 5 amino acids in their sequence ( Table 1 ). The binding selectivity of the phage clones for the different mammalian EphB receptors was also determined (Table 1) . Interestingly, many of the clones identified by panning on EphB1 or EphB2 bind to both receptors, whereas the clones isolated by panning on EphB4 all bind to this receptor with high selectivity. Consistent with this, an alignment of the peptide sequences (Table 1) shows similarities between the EphB1-and EphB2-binding peptides, while the EphB4-binding peptides have more divergent sequences. For example, the THWK phage clone identified by panning on EphB1 and all but one of the clones isolated by panning on EphB2 display related peptides that contain the motif HW (Table 1 ). This motif is not present in any of the EphB4-binding phage clones. Interestingly, the EWLS EphB1-specific clone contains the sequence SPNL, which is found in the G-H loop of ephrin-B2 and ephrin-B3, and the EphB4-binding TNYL and FSPQ peptides contain the sequences FSPN and FSP, respectively, which are found in the G-H loop of ephrin-B1 and ephrin-B2. Two other EphB4-binding clones (DALN and DHNH) contain the sequence NxWxL (where x is a non-conserved amino acid), which is present in the G-H loop of ephrin-B2 and ephrin-B3. Other EphB4-binding clones were aligned in correspondence of only the carboxy-terminal half of the ephrin G-H loop. Binding curves obtained using different phage concentrations suggest that these clones have lower binding avidity for EphB4 (data not shown).
Different Peptides Compete with Each Other for Binding to the EphB Receptor Used for Their
Isolation-To determine whether different phage clones target overlapping Eph receptor binding sites, we chemically synthesized the EWLS EphB1-binding peptide and the TNYL EphB4-binding peptide. We chose these peptides because they contain sequence motifs found in the ephrins and they bind specifically to EphB1 or EphB4, respectively, when displayed on phage (Table 1) . We also synthesized the SNEW EphB2-binding peptide, which is one of the few peptides identified that binds with high selectivity to EphB2 and was displayed on multiple phage clones (Table 1) . Several other peptides were also synthesized. We chose them based on a combination of criteria, including: (i) the sequence similarity of the peptide to the ephrin-B G-H loop; (ii) the number of phage clones isolated displaying that peptide; and (iii) representation of different sequence motifs (Table 1) .
As expected, the EWLS, SNEW, and TNYL peptides efficiently inhibit binding of the corresponding phage clone to the appropriate immobilized EphB receptor (Fig. 2, top panels) . Each peptide also inhibits binding of all the other phage clones that were isolated using the same EphB receptor (Fig. 2 These results suggest that all but one of the peptides identified by panning on an EphB receptor bind to the same region of that receptor. Based on the sequence similarity of some of the peptides with the ephrin G-H loop, the common binding site presumably corresponds to the ephrin high-affinity binding interface of the Eph receptors. It will be interesting to determine the mode of binding of the DALN peptide, which does not compete with other EphB4-binding peptides despite an apparent sequence similarity with the ephrin G-H loop.
Peptides That Selectively Antagonize Ephrin Binding to the EphB1, EphB2, and EphB4
Receptors-Peptides that bind to the same receptor region as the ephrins would be expected to inhibit Eph receptor-ephrin association, if they interact with sufficient affinity. We tested a number of synthetic peptides for their ability to inhibit binding of alkaline phosphatase-tagged ephrin-B2 (ephrin-B2-AP) to EphB receptors (Fig. 3) . Most of the peptides were synthesized with a biotin tag and immobilized on streptavidin plates to verify their ability to capture the EphB ectodomains used for their isolation (data not shown). Only the IPWT peptide failed to bind the EphB receptor (EphB4), presumably because its affinity is too low. Therefore, IPWT was not used for further experiments. The EWYM, TYFD, and FSPQ peptides were not synthesized with a biotin tag and therefore were tested directly for inhibition of ephrin-B2 binding.
Of the peptides tested for their ability to inhibit ephrin binding to EphB receptors, EWLS and AHTF inhibit ephrin binding to EphB1; SNEW (but not DHWRI, SHWP, or SHWT) inhibits ephrin binding to EphB2; and both TNYL and DHNH (but not NPVI or DALN) inhibit ephrin binding to EphB4 (Fig. 3 , left panels and data not shown). The concentration of biotinylated peptides necessary to inhibit binding of the dimeric ephrin-B2 AP by 50% (IC 50 (Fig. 3 , left panels, and Table  1 ). The IC 50 values for the EWLS and SNEW peptides synthesized without the carboxy-terminal biotinylated linker are similar, whereas the IC 50 for the non-biotinylated TNYL peptide is substantially higher than for biotinylated TNYL (150 mM). The EWLS, SNEW, and TNYL peptides are selective because they antagonize ephrin binding to only one EphB receptor (Fig. 3, right panels) . In contrast, the AHTF peptide inhibits ephrin-binding to several EphB receptors (data not shown).
The SNEW peptide Inhibits EphB2 Signaling and Biological Effects-Preincubation of COS cells with the SNEW peptide blocks the ability of ephrin-B1 Fc to induce tyrosine phosphorylation, and therefore activation, of endogenous EphB2 (Fig. 4A) . Futhermore, SNEW inhibits the COS cell retraction phenotype that occurs when EphB2 signaling is stimulated by ephrin-B1 Fc (Fig.  4B,C) . Thus, SNEW can be used to block the biological effects of the EphB2 receptor. In contrast, EWLS at concentrations up to 200 mM does not inhibit endogenous EphB1 tyrosine phosphorylation following ephrin-B1 Fc stimulation of human aortic endothelial cells and TNYL at concentrations up to 350 mM does not inhibit endogenous EphB4 tyrosine phosphorylation following ephrin-B2 Fc stimulation of MCF7 and MDA-MB-231 breast cancer cells (data not shown).
EphB-Binding Peptides as Targeting Agents-In addition to inhibiting the ability of Eph receptors to bind ephrins and elicit biological responses, EphB-binding peptides can serve to selectively target other molecules, such as drugs or imaging probes, to EphB receptor-expressing cells. A stringent assay to determine the receptorbinding specificity of the peptides uses biotinylated peptides immobilized on straptavidin plates, which capture dimeric EphB Fc with high avidity (the apparent dissociation constants are in the low nM range (data not shown)). These experiments show that EWLS and all the EphB4-binding peptides tested bind selectively to EphB1 or EphB4, respectively, and not any other A-or Bclass Eph receptors, while SNEW exhibits some binding to EphA3 in addition to EphB2 (Fig. 5A  and data not shown) . In contrast, the AHTF, SHWPI, WHWT, and DHRWI peptides are less specific and exhibit substantial binding to several EphA and EphB receptors (data not shown).
The ability of the peptides to bind in a stable manner, which is important for both targeting and competitive inhibition, was tested in pull-down experiments. Endogenous EphB receptors were isolated from lysates of mouse brain or cultured cells using the EWLS, SNEW, and TNYL peptides immobilized on streptavidin beads (Fig. 5B) . The NPVI peptide could be used to isolate EphB4 from transfected cells but not endogenous EphB4 from MCF7 cells, which is present at lower levels (Fig. 5B) . These results suggest that EWLS, SNEW, and TNYL dissociate slowly, thus mediating stable binding that persists during the washing steps. EphB receptors were not detected bound to the beads coated with the other peptides. The DALN and DHNH peptides were ineffective when used either alone or together, even though the phage competition experiments suggest that these two peptides bind to distinct sites of EphB4 and might therefore be expected to act synergistically.
To demonstrate the targeting ability of EphB receptor-binding peptides, the TNYL peptide was used to mediate binding of fluorescent streptavidin-coated quantum dot nanocrystals to cells expressing transfected as well as endogenous EphB4 (Fig. 5C ). TNYL can also bind to EphB4 even after fixation of the cells with 4% formaldehyde, suggesting that the peptide binding site on the receptor is not disrupted by the fixation procedure (data not shown).
Optimization of the TNYL EphB4-Binding Peptide-Inspection of the EphB4-binding peptide sequences revealed the consensus motifs GP (see Discussion) and RAW in the peptides that align in correspondence of the carboxy-terminal portion of the ephrin G-H loop (Table 1 ). The GP motif aligns with the GP motif of TNYL and the RAW motif aligns precisely next to the last amino acid of TNYL. This suggests that a TNYL peptide containing the RAW consensus motif at its carboxy terminus might bind better to EphB4 (27) . We generated the non-biotinylated form of this TNYL-RAW peptide (TNYLFSPNGPIARAW) and found that it inhibits ephrin-B2 AP binding to EphB4 with an IC 50 of ~15 nM (Fig. 6A) . Remarkably, this value is 10,000 times lower than the IC 50 of ~150 mM for the non-biotinylated TNYL (Fig. 6A) and comparable to the IC 50 of ~9 nM for the dimeric ephrin-B2 Fc (Fig. 6B) . Despite the dramatically increased ability to bind EphB4, the TNYL-RAW peptide retains high selectivity and does not inhibit ephrin-binding to other EphB receptors even at concentrations much higher than those sufficient to inhibit ephrin binding (Fig. 6C) . The TNYL-RAW peptide also inhibits EphB4 tyrosine phosphorylation induced by ephrin-B2 Fc stimulation of MCF7 cells as well as basal EphB4 tyrosine phosphorylation, which is presumably due to stimulation by low levels of endogenously expressed ephrin-B2 (Fig. 6D ).
DISCUSSION
We have identified a collection of peptides that bind to different EphB receptors by screening phage displaying a library of random 12 amino acid-long linear peptides. These peptides have different sequences and a range of binding affinities. Competition experiments and sequence alignments suggest that all the peptides, with the possible exception of one, target the ephrinbinding site of each Eph receptor, even though the entire EphB ectodomain was used for panning. This is consistent with previous results with peptides that bind to EphA receptors (20, 21) and with the propensity of phage-displayed peptides to target the binding interfaces of proteins (28) (29) (30) . The EphB-binding peptides probably mimic the continuous sequence of the ephrin-B G-H loop, which is 15 amino acids long. In the crystal structure of the ephrin-B2-EphB2 complex, this loop of ephrin-B2 inserts into a cleft of EphB2 and dominates the high affinity receptor-ligand interface (16, 22) .
Although only some peptides contain amino acids that are conserved in the G-H loop of the Bclass ephrin-Bs (highlighted in red in Table 1) , similarities between the peptides allowed the assembly of an overall alignment ( Table 1) . The best EphB1-and EphB4-binding peptides identified in the screens, EWLS and TNYL, have four consecutive amino acids in common with the amino-terminal portion of the ephrin G-H loop, which is the portion of the loop that contributes most of the contacts with the Eph receptor (22) . However, each peptide also has distinctive sequence features, in agreement with its selective binding to only one EphB receptor.
The alignment reveals other interesting features of the peptides. The great majority of the peptides have a proline (highlighted in blue in Table 1 ) in correspondence of the tryptophane at the tip of the ephrin G-H loop (22) . Although proline is not similar to tryptophane, it introduces a bend in the peptides that may mimic the bend at the tip of the G-H loop (22) . Further supporting the idea that the proline may be structurally important, in many of the EphB4-binding peptides a glycine precedes the proline and it is known that in the appropriate sequence context the glycineproline (GP) motif greatly stabilizes the structure of short peptides by promoting a b -hairpin structure even in the absence of disulfide bonds (31) (32) (33) . The GP motif is known to play a critical role in a high-affinity cyclic peptide that binds to the erythropoietin receptor (34, 35) . In this erythropoietin-mimic peptide, the GP motif introduces a b-turn structure linking two short bstrands, and it also mediates important contacts with the erythropoietin receptor. Several phage libraries displaying cyclic peptides that contain a central GP motif have been successfully used to identify structurally constrained peptides that bind with high affinity to cell surface receptors (29, 36, 37) . Interestingly, the EphB4-binding peptides containing the GP motif were isolated from an unbiased and linear peptide library.
In the EphB1-and EphB2-binding peptides the proline is not preceded by glycine, suggesting that the particular type of b-turn induced by the GP motif (31) is not important for interaction with the binding sites of these other EphB receptors. The THWC EphB2-binding peptide is one of the few peptides that does not contain the conserved proline. However, this peptide is probably a disulfide-bonded cyclic peptide that forms a loop with a tip in correspondence of the tip of the ephrin G-H loop (22) . This supports the idea that most of the peptides that we have identified mimic the G-H loop of the ephrins, albeit through different mechanisms. Finally, instead of the proline found in most other peptides, three of the EphB4-binding peptides contain a tryptophane, which is conserved in the G-H loop of the preferred ligand for EphB4, ephrin-B2 (38) .
Phage display is a powerful approach to identify competitive antagonists and ligand mimics, but the peptides isolated are typically of low affinity and often need to be optimized by further "affinity maturation" (29, 30, 39, 40) , introduction of conformational constraints (30, 41) , or crosslinking to increase valency (36, 42, 43) . To optimize the TNYL peptide, we have used a different approach. This approach is modeled on methodologies that take advantage of structural information to appropriately link two low-affinity ligands in order to obtain a much higher affinity bidentate ligand (27, 44) . We noticed that although TNYL competes with all other EphB4-binding peptides, based on the alignment the binding sites probably overlap only in part. TNYL presumably mimics the contacts of the amino-terminal portion of the ephrin G-H loop with EphB4. In contrast, many peptides containing the motif "RAW" presumably mimic the contacts of the carboxyterminal part of the loop, even though the RAW sequence motif is completely divergent from the corresponding residues of ephrin-B2 (Table 1) . This divergence might contribute to the selectivity of the peptides. Thus, to expand the contact sites of TNYL with EphB4 and enhance binding affinity, we linked the RAW tripeptide to TNYL in the appropriate position based on the information provided by the sequence alignment.
Joining the different sequence motifs was extremely effective in enhancing the binding affinity. The TNYL-RAW peptide inhibits binding of the dimeric ephrin-B2 AP to EphB4 with an IC 50 value of approximately 15 nM, which suggests that the K D for binding of TNYL-RAW to EphB4 is in the same range as the K D s for monovalent Eph-ephrin interactions (16 nM for EphB2-ephrin-B2 and 10-12 nM for EphA3-ephrin-A5) (45) (46) (47) . In fact, the IC 50 value for the dimeric ephrin-B2 Fc is only slightly lower (~9 nM). The potency of TNYL-RAW as an antagonist is remarkable considering the absence of a disulphide bond in this peptide. It suggests that TNYL-RAW must nevertheless have an appropriately restrained conformation to avoid a large loss of entropy upon EphB4 binding, which would compromise the binding affinity. It will be interesting to investigate whether the TNYL-RAW peptide forms a b-hairpin and/or dimerizes, similar to the previously described erythropoietin-mimic peptide (35) . It will also be interesting to determine how TNYL-RAW as well as the other peptides fit in the ephrin-binding cleft of the Eph receptors and identify the precise molecular contacts involved.
Many of the peptides identified based on their binding to EphB1 or EphB2, can bind to both receptors ( Table 1 ), suggesting that the ephrinbinding pockets of these receptors are closely related. Indeed, the residues of EphB2 that contribute to the high affinity interface with ephrin-B2 (22) are highly conserved in EphB1 (85% amino acid identity between the mouse sequences), but not in EphB4 (42% identity). Overall, the ephrin-binding domains of mouse EphB1 and EphB2 are 77% identical to each other, but only 46% and 43% identical to the ephrinbinding domain of mouse EphB4, respectively. It is therefore not surprising that the peptides that bind to EphB1 and EphB2 are more similar to each other than to the EphB4-binding peptides.
Both EphB2 and EphB4 are overexpressed in a wide variety of cancers (3, 48) and peptides that bind to these receptors could be developed for imaging and drug targeting applications. Even the non-optimized TNYL peptide effectively delivers fluorescent quantum dots to EphB4-expressing cells. Furthermore, an anti-EphB2 antibody conjugated to a cytotoxic drug has been shown to significantly retard tumor growth in mouse xenograft models of human colon cancer (48) . There are also many possible uses for EphB receptor antagonists, particularly in cancer therapy. For example, we have recently reported that the interplay between EphB4 expressed in breast cancer cells and ephrin-B2 expressed in the tumor vasculature promotes tumor growth by stimulating angiogenesis through signals mediated by the cytoplasmic domain of the transmembrane ephrin-B2 ligand (8) . Thus, the TNYL-RAW peptide could be developed to inhibit tumor progression and other forms of pathological angiogenesis that may similarly depend on EphB4 and ephrin-B2. It would also be interesting to test combinations of peptides binding to A-and Bclass Eph receptors involved in a particular pathological process, such as EphB4 and EphA2 in cancer (5, 8, 49, 50) . Finally, the affinity of the EphB receptor binding peptides may be greatly increased by dimerization through a flexible linker (36, 42, 43) . However, it is possible that the dimerized peptides may become agonists.
The EphB receptor antagonists identified here should be useful for the development of therapeutic tools and to allow further characterization of the physiological processes regulated by specific EphB receptors.
FIGURE LEGENDS
FIG. 1. Enrichment of phage clones that bind to EphB receptors. An M13 phage library displaying random 12-mer peptides was incubated in wells coated with the ectodomain of EphB1, EphB2, EphB4, or BSA (control) and binding phage were recovered by low pH elution. Phage recovered after the first round of panning (1*) were not quantified to ensure that rare clones would be recovered. Phage PFUs (plaque forming units) are shown for rounds 2 to 4, and error bars indicate standard deviation. Two panning experiments were performed for EphB4: the first is shown on the left and the second on the right. In the EphB1 panning, only the blue plaques from peptide-displaying phage were counted in rounds 3 and 4 because there were many white plaques (indicative of phage not displaying any peptide). In the EphB2 panning and the second EphB4 panning, round 3 was repeated twice from round 2 using two different concentrations of receptor ectodomain for coating the wells: 10 mg/ml for round 3.1 and 1 mg/ml for round 3.2. In round 4 for EphB2 and EphB4 (performed using phage from round 3.2), the wells were coated with 1 mg/ml receptor. In all other rounds, 10 mg/ml receptor were used for coating.
FIG. 2. Competition between peptides for binding to EphB receptors. (EphB1)
Top panel, the EWLS peptide inhibits binding of EWLS phage to the immobilized EphB1 ectodomain in a concentrationdependent manner. Bottom panel, the EWLS peptide at 5 mM inhibits EphB1 binding of the phage clones isolated by panning on EphB1. SNEW was used as the control peptide in both panels. (EphB2) Top panel, the SNEW peptide inhibits binding of SNEW phage to the immobilized EphB2 ectodomain in a concentration-dependent manner. RTVA (see Materials and Methods) was used as the control peptide. Middle and bottom panels, the SNEW peptide at 25 mM inhibits EphB2 binding of most phage clones isolated by panning on EphB2. The only exceptions are the IHWP, DHRWV and WHWT clones. However, binding of these clones is inhibited by 50 mM SNEW peptide, particularly when the phage concentration is halved. RTVA was used as the control peptide with SNEW phage in the middle panel and SNEW was used as a control with the TNYL EphB4-binding phage in the bottom panel. (EphB4) Top panel, the TNYL peptide inhibits binding of TNYL phage to the immobilized EphB4 ectodomain in a concentration-dependent manner. Middle panel, the TNYL peptide at 25 mM inhibits binding to EphB4 of the phage clones that were isolated by panning on EphB4, except for the DALN clone. The SWL EphA2-binding peptide (20) was used as the control peptide in both top and middle panels. Bottom panel, the DALN peptide (but not the DHNH and NPVI peptides) inhibits binding of DALN phage to the immobilized EphB4 ectodomain in a concentration-dependent manner. Bound phage were detected using anti-M13 phage antibody coupled to HRP and phage binding in the presence of peptide was normalized to phage binding in the absence of peptide. Error bars indicate standard deviation from duplicate measurements, and were calculated taking into account propagation of errors. . A 10 sec exposure shows that the TNYL-RAW peptide inhibits the phosphorylation of EphB4 induced by ephrin-B2 Fc, whereas a 2 min exposure shows that the peptide also inhibits the low levels of EphB4 phosphorylation that are presumably due to endogenously expressed ephrin-B2. The filters were reprobed with EphB4 antibodies to confirm equal amounts of immunoprecipitated receptor. 
